Please login to the form below

Not currently logged in
Email:
Password:

BeiGene

This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license

Latest news

More from news
Approximately 11 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to

  • Deal Watch March 2017 Deal Watch March 2017

    In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest appointments

  • New hires at EMA, Gilead and BeiGene New hires at EMA, Gilead and BeiGene

    EMA gains a new executive director, Gilead appoints a new senior vice president and BeiGene hires a new chief business exec. ... BeiGene. BeiGene has appointed Angus Grant (pictured above) as chief business executive.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics